<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Exploring AlphaFold 3 for CD47 Antibody-Antigen Binding Affinity: An Unexpected Discovery of Reverse docking - Health AI Hub</title>
    <meta name="description" content="This paper investigates AlphaFold 3's (AF3) capabilities for predicting antibody-antigen (CD47) complex structures and analyzing binding affinity for therapeuti">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>Exploring AlphaFold 3 for CD47 Antibody-Antigen Binding Affinity: An Unexpected Discovery of Reverse docking</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2511.14676v1" target="_blank">2511.14676v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-11-18
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Yiyang Xu, Ziyou Shen, Yanqing Lv, Shutong Tan, Chun Sun, Juan Zhang
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> q-bio.BM
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 0.90 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2511.14676v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2511.14676v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This paper investigates AlphaFold 3's (AF3) capabilities for predicting antibody-antigen (CD47) complex structures and analyzing binding affinity for therapeutic antibody pre-screening. It demonstrates AF3's promise for accurate structure and binding energy predictions, while also uncovering an unexpected "reverse docking" phenomenon attributed to its advanced AI architecture.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This research is highly relevant for accelerating drug discovery and development by validating and improving advanced AI tools like AlphaFold 3 for efficient identification and optimization of therapeutic antibodies. Accurate prediction of antibody-antigen interactions can significantly streamline the lead identification and optimization processes, especially for critical targets like CD47 in cancer therapy.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>The paper investigates the use of AlphaFold 3 for AI-driven drug discovery, specifically for predicting antibody-antigen binding affinities to identify and optimize potential therapeutic antibodies (e.g., for cancer treatment). It explores AI-assisted lead identification and optimization processes, aiming to accelerate the development of new medicines. The discussion of the 'reverse docking' phenomenon and its implications for 'optimization and design direction of AI for structural prediction' directly contributes to improving the reliability and architecture of medical AI tools.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>Evaluated AlphaFold 3 (AF3) for predicting challenging antibody-antigen (CD47) complex structures, a domain with limited resolved crystallographic data.</li>
                    
                    <li>Assessed AF3's potential to perform pre-screening for potent antibody candidates through binding affinity analysis, comparing its performance with commercial molecular docking software.</li>
                    
                    <li>AF3 demonstrated high efficiency and reliability in producing accurate molecular structures and subsequent binding energy predictions for the majority of subjects.</li>
                    
                    <li>Discovered an unexpected and nonrandom "reverse docking" phenomenon for two antibody subjects, suggesting novel issues stemming from AF3's revolutionized AI model architectures.</li>
                    
                    <li>Analysis and error correction experiments indicate that the "reverse docking" phenomenon is likely caused by the advanced AI architecture of AF3.</li>
                    
                    <li>The research suggests AF3's potential extends beyond antibody-antigen binding affinity to predicting various chemical or physical properties of drug candidates based on its accurate structural predictions.</li>
                    
                    <li>Findings provide crucial insights and reminders for the optimization and future design direction of AI models for structural prediction, particularly regarding architectural nuances.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>The study utilized AlphaFold 3 to predict the structures of antibody-antigen (specifically CD47) complexes. These predicted structures were then employed to analyze binding affinity, likely through subsequent computational methods, and the results were benchmarked against molecular docking modules from commercial software. An in-depth analysis and error correction experiments were conducted to understand the observed "reverse docking" phenomenon.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>AlphaFold 3 efficiently produces highly reliable molecular structures and subsequent binding energy predictions for most antibody-antigen complexes, positioning it as a strong competitor for pre-screening antibody candidates. However, an unexpected "reverse docking" phenomenon was observed for two antibody subjects, which analysis suggests is a consequence of AF3's revolutionized AI model architectures.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>The ability of AF3 to accurately predict antibody-antigen binding affinities can significantly expedite the identification and optimization of therapeutic antibody candidates, potentially reducing the time and cost in drug development pipelines. This is particularly impactful for developing new biotherapeutics targeting disease-relevant proteins like CD47, which is a key target in cancer immunotherapy.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The unexpected "reverse docking" phenomenon observed for certain antibody subjects highlights a potential limitation or a new challenge arising from the advanced AI model architectures of AlphaFold 3. This indicates that while AF3 is generally reliable, specific architectural quirks might lead to anomalous predictions in some cases, requiring further understanding and mitigation.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>The discovery of "reverse docking" provides critical experience and guidance for future research into optimizing and refining the design of AI models for structural prediction. This suggests a need to investigate and understand how revolutionized AI architectures influence binding predictions, to ensure robust and universally reliable outcomes from such advanced computational tools.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Immunology</span>
                    
                    <span class="tag">Oncology</span>
                    
                    <span class="tag">Drug Discovery</span>
                    
                    <span class="tag">Structural Biology</span>
                    
                    <span class="tag">Bioinformatics</span>
                    
                    <span class="tag">Biotherapeutics</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">AlphaFold 3</span>
                    
                    <span class="tag tag-keyword">CD47</span>
                    
                    <span class="tag tag-keyword">antibody-antigen</span>
                    
                    <span class="tag tag-keyword">binding affinity</span>
                    
                    <span class="tag tag-keyword">molecular docking</span>
                    
                    <span class="tag tag-keyword">drug discovery</span>
                    
                    <span class="tag tag-keyword">reverse docking</span>
                    
                    <span class="tag tag-keyword">AI structural prediction</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">AlphaFold 3 (AF3) is a powerful biomolecular structure-predicting tool based on the latest deep learning algorithms and revolutionized AI model architectures. A few of papers have already investigated its accuracy in predicting different biomolecular structures. However, the potential applications of AF3 beyond basic structure prediction have not been fully explored. In our study, we firstly focused on structure predictions of antibody-antigen (CD47) complexes, which is believed to be challenge for AF3 due to limited resolved cognate crystallographic structures. Furtherly, we aimed to the potentiality of AF3 in performing pre-screening for potent antibody candidates as an auxiliary work through binding affinity analysis compared to other molecular docking modules of commercial software, which would greatly benefit the lead identification or optimization process in the drug development. In essence, this is not limited to antibody-antigen binding affinity, but many other chemical or physical properties of any drug candidate based on AF3's accurate predicting structures that are extremely close to the reality. According to our experimental results, AF3 is a very promising competitor, which can efficiently produce highly reliable molecular structures and subsequent binding energy predictions for most subjects. Surprisingly, an unexpected and nonrandom phenomenon "reverse docking" was observed for two of our antibody subjects, suggesting new issues arising from the architectural revolution of AF3. Our analysis and error correction experiments show that this phenomenon is likely to be caused by revolutionized AI model architectures, which provides important experience and reminders for the optimization and design direction of AI for structural prediction. All software copyrights belong to the China Pharmaceutical University (CPU) and its affiliated School of Pharmacy and School of Science.</p>
            </section>

            
            <section class="paper-section">
                <h2>Comments</h2>
                <p>15 pages,4 figures, submitted to ACS Omega</p>
            </section>
            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>